Peptide therapy accusations: separating signal from noise

What did @hackiebackup actually say?

The creator's core argument is essentially: slow down before calling this a scam. They point out that accusations of fraud surrounding Bioglutide, a compound marketed by BioMed Industries as a superior GLP-1 alternative, are themselves mostly unverified. Their position is that "nothing has definitively proved that this product is 100% fake." They're not endorsing the product. They're pushing back on what they see as premature mob certainty. That's a fair epistemological point to make, even if the surrounding context gives serious pause.

The creator also raises a practical question worth examining: can outside labs actually verify whether Bioglutide is what it claims to be, given that its structure hasn't been publicly disclosed? And they note the company's website still lists active clinical trial recruitment as evidence that something is still happening. Whether that evidence holds up is a different story.

Does the science back this up?

Here's where things get complicated fast. The premise that Bioglutide could cause significant weight loss without muscle loss is an extraordinary claim. Existing GLP-1 receptor agonists like semaglutide do cause meaningful lean mass reduction alongside fat loss. Wilding et al. (2021, New England Journal of Medicine) found semaglutide produced roughly 15% body weight reduction, but a notable portion was lean mass. A compound that could selectively target fat while preserving muscle would represent a genuinely novel mechanism, and that mechanism has not been published in any peer-reviewed journal for Bioglutide.

The creator's implicit standard, wait for published clinical trial results, is scientifically sound in principle. Peer review exists for a reason. But legitimate pharmaceutical development leaves a paper trail: IND applications, registered trials on ClinicalTrials.gov, institutional review board approvals. As of the time of this writing, no Bioglutide trials appear in major registries. A website listing "clinical trials" is not the same as a registered, audited clinical trial. That distinction matters enormously.

What did they get wrong (or right)?

The creator deserves credit for one thing: epistemic humility is genuinely underrated in the peptide community, where both hype and dismissal tend to outrun evidence. Their challenge, "what did you test, how do you know how this is supposed to be structured," is actually a reasonable question about methodology. If no reference standard exists for Bioglutide's molecular structure, third-party lab testing faces a real analytical problem.

But here's what they got wrong. They treat the absence of definitive proof of fraud as rough equivalent to evidence of legitimacy. That's not how the burden of proof works in regulated medicine. Companies making efficacy claims before publishing peer-reviewed data carry the burden of proof, not the skeptics. The Wolf of Wall Street rehabilitation analogy is also doing a lot of work in this argument. Jordan Belfort's post-prison career doesn't rehabilitate unverified medical product claims. Character redemption and product legitimacy are separate questions entirely.

The creator also understates what "invest" might mean for everyday consumers. People aren't just investing money in this company. Some may be ingesting unverified compounds.

What should you actually know?

The GLP-1 drug class is genuinely competitive and rapidly evolving. Tirzepatide (GIP/GLP-1 dual agonist) already outperformed semaglutide on weight outcomes in the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine). Multiple companies are legitimately racing to develop next-generation obesity drugs. That competitive context makes it plausible that someone would claim to have a breakthrough compound, and it also makes the space fertile ground for fraud.

For consumers, the practical question isn't whether Bioglutide is theoretically possible. It's whether there is any verifiable, peer-reviewed, registry-confirmed evidence that this specific product does what its makers claim. Right now, that answer is no. "Wait and see" is a reasonable personal posture for someone not spending money or ingesting the product. It is not a sufficient reason to dismiss legitimate fraud concerns raised by regulators or researchers who have reviewed the company's claims more closely than a TikTok video can.

• No Bioglutide trials appear in ClinicalTrials.gov as publicly registered studies.
• The FDA has not approved Bioglutide or recognized it as an investigational new drug publicly.
• A company website listing trials is marketing, not clinical evidence.
• Third-party lab verification challenges are real but do not prove product legitimacy by default.